Smartlab Europe

Drug Research

Nimbus, Lilly Ink Licence Agreement on Treatments in Obesity

Nimbus Therapeutics has announced that it has entered into a multi-year research partnership and a $1.3 billion exclusive license agreement with Eli Lilly in order to develop oral treatments in obesity as well as other metabolic diseases. Lilly, which very...

Sanofi, Earendil Partner on Autoimmune Disease Treatments

Sanofi and Earendil Labs have announced a strategic collaboration effort that goes on to apply the discovery platform from Earendil across many of the Sanofi autoimmune and inflammatory disease programs. The two AI-powered research and development platforms from Earendil Labs concerning protein therapeutics go on...

Insilico and Servier Join Hands for New Oncology Therapies

Insilico Medicine has gone ahead with a multi-year research and development - R&D collaboration with Servier, of almost $888m, in order to develop and discover certain new oncology therapies. The partnership combines the AI drug discovery platforms of Insilico...

Specialized Laboratory Equipment Requirements for Biologics and Biosimilar Development

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.

Next-Generation Laboratory Equipment Redefining Drug Discovery Workflows

Advanced technologies such as AI-integrated high-throughput screening platforms and automated assay systems are fundamentally transforming early-stage pharmaceutical research. These innovations address critical bottlenecks in productivity and data quality, enabling research teams to accelerate timeline-to-candidate selection while enhancing the predictive accuracy of drug discovery campaigns.

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »